20 March 2015
Whether or not you get the benefit of decreased colorectal cancer risk by taking aspirin may come down to the variants you have at two spots in your genome, as GenomeWeb has reported.
A study appearing in the Journal of the American Medical Association this weekfrom Colon Cancer Family Registry and the Genetics and Epidemiology of Colorectal Cancer Consortium project researchers reports that this 30 percent decrease in colorectal cancer risk disappears in people with rare variants at sites on chromosomes 12 and 15. They examined this effect in 8,634 people with colorectal cancer and 8,553 controls.
In people with these some rare variants, aspirin use actually increased their risk of colorectal cancer.
This is a step toward the personalization of medicine and tailored preventive care, says Richard Wender from the American Cancer Society and Thomas Jefferson University in a related JAMA editorial.
"I anticipate the time when genome sequencing to determine a lifelong (colorectal-cancer) prevention and screening strategy is a reality, although it's some time off," Wender tells Reuters.
Print16 May 2024
NovaMedica team participates in the Russian Pharmaceutical Forum in St. Petersburg
14 May 2024
27 April 2024
The Moscow Department of Clinical Research processed 78 applications for drug trials over two years
21 May 2024
Cell therapy could help curb progression of heart failure
20 May 2024
China may find various medicines from the Gamaleya Center interesting
20 May 2024
The number of conducted clinical trials in Russia is growing
17 May 2024